A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I, Open-label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Effects of M1-c6v1 for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06046742
• Other study ID #: VRT106-J01
• Status: Recruiting
• Phase: Phase 1
• Start date: May 10, 2024
• Est. completion date: December 20, 2026

Study information

• Verified date: December 2023
• Source: Guangzhou Virotech Pharmaceutical Co., Ltd.
• Contact: Guangzhou Virotech Pharmaceutical Co., Ltd.
• Phone: +86-020-32030725
• Email: clinicaltrialinfo[@]virot.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Description:

This study is an open-label, dose-escalation clinical study which aims to evaluate the safety and tolerability of multiple IV injections of M1-c6v1 in subjects with locally advanced/metastatic solid tumors, as well as evaluating the biological distribution characteristics and biological effects of M1-c6v1 (i.e., virus tissue distribution and shedding characteristics), evaluating immunogenicity of M1-c6v1, and preliminarily exploring the anti-tumor effects of M1-c6v1.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 12
• Est. completion date: December 20, 2026
• Est. primary completion date: August 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects must have diagnosis of locally advanced or metastatic solid tumors who are intolerable or refractory to the standard therapy.

2. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.

3. Males and females at least 18 years of age, inclusive, at the Screening Visit.

4. Have at least one measurable lesion.

5. An Eastern Cooperative Oncology Group (ECOG) score of 0-1, 1 week before the first administration of IMP.

6. An estimated survival time of = 12 weeks.

Exclusion Criteria:

1. Subject has a history of primary or acquired immunodeficient states, leukemia, lymphoma, acquired immunodeficiency syndrome (AIDS) or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.

2. Subject has received any anti-tumor treatment 4 weeks before using the IMP, including chemotherapy, biological therapy, endocrine therapy, targeted therapy, immunotherapy.

3. Subject has received systemic glucocorticoids (prednisone >10 mg/day or equivalent doses of similar drugs) or other immunosuppressive agents within 14 days prior to first administration of IMP.

4. Subject has received immunomodulatory drugs, including but not limited to thymosin, IL-2, IFN, etc. within 14 days prior to first administration of IMP.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Biological:
• M1-c6v1
Intravenous drip administration

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital East	Kashiwa-shi	Chiba
Japan	St. Marianna University Hospital	Kawasaki-shi	Kanagawa
Japan	National Hospital Organization Shikoku Cancer Center	Matsuyama-shi	Ehime

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Virotech Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the safety and tolerability of escalating doses of intravenous M1-c6v1 in Patients with advanced malignant tumors	Monitor the incidence of adverse events (TEAEs) during the study.	About 2 years
Primary	Evaluate dose-limiting toxicities (DLTs) and determine the recommended phase 2 dose (RP2D) of single-agent intravenous administration of M1-c6v1.	Incidence of DLT	About 2 years
Primary	Conduct a dose extension study to evaluate the safety and tolerability of intravenous administration of M1-c6v1 at maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.	Monitor the incidence of adverse events (TEAEs) during the study.	About 2 years
Secondary	Examine the biological distribution characteristics and shedding patterns of intravenously administered M1-c6v1.	Measure the distribution and shedding of M1-c6v1 following intravenous injection by detecting its presence in blood, saliva, urine, nasal swabs, and feces using qPCR (quantitative polymerase chain reaction) method.	About 2 years
Secondary	Assess the immunogenicity of intravenous administration of M1-c6v1.	Detect the presence of neutralizing antibodies against M1-c6v1 and assess their titers, which represent the potency of the neutralizing antibodies, using the PD50 value.	About 2 years
Secondary	Assess the anti-tumor effect of M1-c6v1, including objective response rate (ORR) and disease control rate (DCR) as efficacy indicators.	Based on the specific tumor types, assess the ORR (Objective Response Rate) and DCR (Disease Control Rate) using RECIST (Response Evaluation Criteria in Solid Tumors) v1.1 or mRECIST (modified Response Evaluation Criteria in Solid Tumors) criteria.	About 2 years